Table 1:

Baseline and treatment characteristics of patients aged 70 years and older evaluated for transplant within one year of diagnosis

	ASCT cohort N (%)	Non-ASCT cohort N (%)	P-value
Total number per group	38	41
Sex			0.02
Male	30 (79)	21 (51)
ISS, (n=61)	n=28	n=32	0.16
Low risk	9 (32)	11 (34)
Intermediate risk	6 (21)	13 (41)
High Risk	13 (47)	8 (25)
High risk cytogenetics, (N=71)	n=33	n=38	0.47
Del 17p, gain 1q, t(14;16), t(14;20) or t(4;14)	15 (45)	13 (34)
Median age, years (range)	71.5 (70–78)	71 (70–77)	0.90
HCT-CI			0.38
0	11 (29)	18 (44)
1–2	16 (42)	13 (32)
≥3	11 (29)	10 (24)
Status at BMT consultation			0.11
On upfront therapy	30 (79)	38 (93)
Previously treated	8 (21)	3 (7)
KPS			0.12
90–100	22 (58)	17 (42)
70–80	16 (42)	21 (51)
<70	0 (0)	3 (7)
Disease status at transplantation evaluation			0.38
Very good partial response + Complete response (VGPR+CR)	24 (63)	28 (68)
Partial response (PR)	13 (34)	10 (24)
Stable disease (SD)	1 (3)	1 (3)
Progressive disease (PD)	0 (0)	2 (5)
Treatment			0.72
Doublet IMiD	3 (8)	1 (2)
Doublet PI	4 (11)	4 (10)
Doublet daratumumab	1 (2)	1 (2)
Triplet Cy + PI	9 (24)	6 (15)
Triplet IMiD + PI	20 (53)	27 (66)
Triplet daratumumab	1 (2)	2 (5)
Conditioning regimen		-
Melphalan 200 mg/m2 + BCNU 300–350 mg/m2	17 (44)
Melphalan 200 mg/m2	12 (32)
Melphalan 140 mg/m2	9 (24)
Maintenance received	21(55)	20(49)	0.65

BCNU: carmustine

Cy: cyclophosphamide

HCT-CI= hematopoietic cell transplantation comorbidity index

ISS= International staging system

IMiD: Immunomodulatory drugs

KPS= Karnofsky performance status

PI: Proteasome inhibitor